Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Trial Profile

A Phase 1/2 Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs AGEN 1884 (Primary) ; AGEN 2034 (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Agenus
  • Most Recent Events

    • 20 Oct 2018 Results presented in an Agenus media release.
    • 20 Oct 2018 According to an Agenus media release, results from this study were presented at the 2018 European Society for Medical Oncology (ESMO) Congress
    • 09 Oct 2018 According to an Agenus media release, data will be presented at the European Society for Medical Oncology (ESMO) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top